Keryx Biopharmaceuticals Contact:Lora PikeSenior Director, Investor RelationsT: email@example.com
BOSTON, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to market for people with renal disease, today announced that it will host a conference call and webcast on Wednesday, November 9, 2016 at 8:00 a.m. ET to discuss its third quarter 2016 financial results and provide corporate updates. To participate in the conference call, please dial 1-888-396-2320 (U.S.), 1-774-264-7560 (international) and refer to conference ID: 11829223. The call will be webcast live with slides and accessible through the Investors section of the company's website at www.keryx.com for a period of 15 days after the call. Keryx Biopharmaceuticals will announce its financial results for this period in a press release to be issued prior to the call. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to market for people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.